Aurigene Pharmaceutical Services Expands with New Facility

News
Article

The facility is based on a state-of-the-art design concept that allows maximum flexibility for a multi-product, multi-platform offering.

Aurigene Pharmaceutical Services, a contract research, development, and manufacturing organization (CDMO), announced on May 22, 2023 the construction of a state-of-the-art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.

The first steps show Aurigene investing $40 million in an R&D and pilot-scale facility at Genome Valley, which is set to meet the process development and clinical supply needs of global biotech companies, according to a company press release. Further, the facility is based on a state-of-the-art design concept that allows maximum flexibility for a multi-product, multi-platform offering.

Set to be fully operational by 2024, the facility hopes to continue to be a strong presence in the biotherapeutics space, as it is complemented by exclusive access to an established large-scale good manufacturing practice (GMP) manufacturing facility with a drug substance capacity of 15kl and fill/finish capabilities. Additionally, another fill/finish line is under construction to be validated before the end of 2024, according to the press release.

“We see an increased outsourcing demand from global biopharmaceutical companies. With this expansion in biotherapeutics CDMO, we will be positioned to provide integrated services from clinical research to commercial manufacturing for small and large molecules,” said Akhil Ravi, CEO of Aurigene Pharmaceutical Services Ltd., in a press release. “Investing in emerging technologies and health solutions reinforces our aim to triple our existing reach to touch over 1.5 billion patients worldwide by 2030.”

Source: Aurigene Pharmaceutical Services

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Related Content